Illumina (NASDAQ:ILMN) reportedly delivered a mixed performance for Q4 2024, with both earnings beats and misses according to various estimates. Despite challenging market conditions, the company presented growth, meeting Q4 sales targets and announcing a promising collaboration with NVIDIA to stimulate genomic advancements. However, analysts reduced their forecast for ILMN following Q4 results, leading to some fluctuation in the stock. Notably, Illumina faced a significant setback as it was listed on China's 'unreliable entity' list, which triggered a fall in its share prices. Nonetheless, Ark Invest doubled down on ILMN while several other shareholders reduced their positions. Additionally, Illumina continued to focus on strategic investments aimed at creating the world's largest genetic database. This included acquiring Fluent BioSciences, expanding its TruSight Oncology portfolio, and launching a significant proteomics program with major players including GSK, J&J, and Novartis. Despite the hurdles, some outlooks remain optimistic, seeing potential for growth in the long term
Illumina ILMN News Analytics from Tue, 09 Jul 2024 07:00:00 GMT to Sat, 08 Feb 2025 18:30:09 GMT -
Rating 0
- Innovation 3
- Information 8
- Rumor -4
